Once‐weekly (70 mg/m(2)) vs twice‐weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials

Combination of carfilzomib with dexamethasone (Kd) is approved for use in relapsed and/or refractory multiple myeloma (RRMM), with carfilzomib administered twice weekly at 56 mg/m(2) (Kd56 BIW) or once weekly at 70 mg/m(2) (Kd70 QW). Post hoc cross‐trial comparisons were performed to compare efficac...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Moreau, Philippe, Stewart, Keith A., Dimopoulos, Meletios, Siegel, David, Facon, Thierry, Berenson, James, Raje, Noopur, Berdeja, Jesus G., Orlowski, Robert Z., Yang, Hui, Ma, Haijun, Klippel, Zandra, Zahlten‐Kumeli, Anita, Mezzi, Khalid, Iskander, Karim, Mateos, Maria‐Victoria
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Cancer Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7196059/
https://ncbi.nlm.nih.gov/pubmed/32108443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2945
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares